ST2 is an IL-1–like receptor for the alarmin IL-33, which is associated with neuroinflammation and vascular dysfunction (68–70), and was recently described as a prognostic marker of neurological sequelae in children with CM (55). This evidence concerns the gene IL33 and cutaneous mastocytosis.